An official website of the United States government
Home
Name
Zynyz
Alternate Names
Retifanlimab
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Monoclonal antibody
NSC Number
None
Primary Site
None
Histology
Remarks
On May 15, 2025, the FDA approved retifanlimab-dlwr (Zynyz, Incyte Corporation) with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The FDA also approved retifanlimab-dlwr, as a single agent, for adults with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.
March 22, 2023 FDA granted accelerated approval to retifanlimab-dlwr (Zynyz), for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).
March 22, 2023 FDA granted accelerated approval to retifanlimab-dlwr (Zynyz), for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).
Coding
This drug should be coded
